It's also being named as super enhanced permeability and retention effect (SUPR).[26] The improvement in efficacy has been reflected in the CD44 targeted anti‐PD‐1 driven PINs compared to the monotherapy.[130] The SUPR effect helps in the uniform distribution of antibodies throughout the tumor.[131] We haven't found any clinical trials with the EPR effect or that are solely based on passive targeting. This evidence concerns the gene PDCD1 and neoplasm.